You are here: Industry Insights > CGRP

News List

Lilly’s CGRP Emgality and Spark’s Luxturna win CHMP backing, as Sarepta’s Exondys misses fiercepharma
September 25, 2018
The European Medicines Agency’s (EMA) drug review panel is on fire this week. It recommended 13 medicines—including Eli Lilly’s CGRP player Emgality—for approval, nixed Sarepta’s controversial Duchenne ...
FDA Approves Ajovy americanpharmaceuticalreview
September 18, 2018
The US Food and Drug Administration (FDA) has approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults...
Teva’s anti-CGRP drug Ajovy cleared for migraine prevention pharmatimes
September 18, 2018
US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
Amgen, Novartis’ migraine therapy impresses again pharmatimes
July 16, 2018
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
Allergan’s experimental migraine drug hits trial targets pharmatimes
July 10, 2018
Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.
Teva and Alder sign global licence agreement on anti-CGRP therapy pharmaceutical-technology
January 11, 2018
Teva Pharmaceuticals International has entered a global licence agreement with Alder BioPharmaceuticals for anti-calcitonin gene-related peptide (CGRP) antibodies and their usage techniques.

Previous page 1 2 Next page